DAPK2 and neoplasm: Studies exploring the selective reconstitution of DAPk2 catalytic activity were first to demonstrate the proof-of-concept strategy of restoring tumor suppressive kinase activity by targeted delivery of actively constituted DAPk in the context of an immunokinase fusion protein.